BACKGROUND: The objective of this study was to evaluate citalopram for executive functioning in Huntington's disease (HD). METHODS: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administeredcitalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning. RESULTS: The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference -0.167; 95% confidence interval [CI], -0.361 to 0.028; P = .092). Citalopram participants showed improved clinician-rated depression symptoms on the HAM-D (t = -2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status. CONCLUSIONS: There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD.
RCT Entities:
BACKGROUND: The objective of this study was to evaluate citalopram for executive functioning in Huntington's disease (HD). METHODS: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning. RESULTS: The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference -0.167; 95% confidence interval [CI], -0.361 to 0.028; P = .092). Citalopramparticipants showed improved clinician-rated depression symptoms on the HAM-D (t = -2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status. CONCLUSIONS: There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD.
Authors: J S Paulsen; H Zhao; J C Stout; R R Brinkman; M Guttman; C A Ross; P Como; C Manning; M R Hayden; I Shoulson Journal: Neurology Date: 2001-08-28 Impact factor: 9.910
Authors: K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson Journal: Neurology Date: 2000-01-25 Impact factor: 9.910
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett Journal: JAMA Date: 2010-01-06 Impact factor: 56.272
Authors: George J Yohrling IV; George C-T Jiang; Molly M DeJohn; Daniel J Robertson; Kent E Vrana; Jang-Ho J Cha Journal: J Neurochem Date: 2002-09 Impact factor: 5.372
Authors: Wenzhen Duan; Zhihong Guo; Haiyang Jiang; Bruce Ladenheim; Xiangru Xu; Jean Lud Cadet; Mark P Mattson Journal: Ann Neurol Date: 2004-04 Impact factor: 10.422
Authors: Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky Journal: J Cent Nerv Syst Dis Date: 2022-05-21
Authors: Diane M Jacobs; M Colin Ard; David P Salmon; Douglas R Galasko; Mark W Bondi; Steven D Edland Journal: Alzheimers Dement (N Y) Date: 2017-09-19
Authors: Tiago A Mestre; Monica Busse; Aileen M Davis; Lori Quinn; Filipe B Rodrigues; Jean-Marc Burgunder; Noelle E Carlozzi; Francis Walker; Aileen K Ho; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins Journal: Mov Disord Clin Pract Date: 2018-05-09